Predicting early relapse in follicular lymphoma: have we turned a corner?
Menée à partir d'échantillons biopsiques prélevés sur 160 patients atteints d'un lymphome folliculaire puis validée à partir d'échantillons tumoraux fixés au formaldéhyde et inclus en paraffine après prélèvement sur 488 patients complémentaires, cette étude internationale évalue la performance d'un système de score, basé sur l'expression de 23 gènes, pour prédire la survie sans progression chez les patients recevant un traitement à base de rituximab
In The Lancet Oncology, Sarah Huet and colleagues1 report a novel prognostic score, derived from the expression profile of 23 genes, that can discriminate between patients with follicular lymphoma at high and low risk of disease progression. Although most patients with follicular lymphoma follow an indolent course, surviving upwards of 20 years after diagnosis, an intractable group of patients has substantially worse outcomes because their cancer is prone to early progression (within 2 years) after treatment (POD-24)2 or undergoes transformation to an aggressive form of lymphoma.
The Lancet Oncology , commentaire, 2017